NEW YORK ( TheStreet) -- Amsurg Corporation (Nasdaq: AMSG) is trading at unusually high volume Thursday with 611,883 shares changing hands. It is currently at 4.1 times its average daily volume and trading up $1.50 (+5.8%) at $27.35 as of four p.m. ET.

Amsurg has a market cap of $808.3 million and is part of the health care sector and health services industry. Shares are up 23.4% year to date as of the close of trading on Wednesday.

AmSurg Corp., through its wholly owned subsidiaries, engages in the development, acquisition, and operation of ambulatory surgery centers in partnership with physicians in the United States. The company has a P/E ratio of 15.3, below the average health services industry P/E ratio of 15.9 and below the S&P 500 P/E ratio of 16.8.

TheStreet Ratings rates Amsurg as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Amsurg Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVUP to 95370 or select from multiple alert options.
null

If you liked this article you might like

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

'Mad Money' Lightning Round: Kroger, Dunkin' Brands

'Mad Money' Lightning Round: Kroger, Dunkin' Brands

Jim Cramer's 'Mad Money' Recap: Trump Trade War Could Hit U.S. Car, Apple iPhone Sales

Jim Cramer's 'Mad Money' Recap: Trump Trade War Could Hit U.S. Car, Apple iPhone Sales

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More

Mednax Remains Unlikely Target as Medical Mergers Gain Steam

Mednax Remains Unlikely Target as Medical Mergers Gain Steam